Overcoming functional and translational challenges of cellular immunotherapies for solid tumors.

In recent years, immunotherapy has revolutionized the landscape of cancer treatment, offering promising avenues for patients with otherwise limited outcomes. Among the most promising modalities are cell-based therapies, including autologous and allogeneic approaches such as engineered T cells, NK cells, stem cells and cell-based vaccines. These therapies harness the inherent capabilities of immune cells to recognize and eliminate cancer cells. Although cell therapies have shown remarkable clinical efficacy in hematologic malignancies, critical hurdles impede their efficacy for the treatment of solid tumors. This review examines the key challenges that hinder the broader clinical-translation of autologous and allogeneic cell-based cancer therapies in treating solid tumors. These include functional challenges that limit therapeutic efficacy and translational challenges that impede the clinical development and implementation of promising cellular therapies. We highlight contributing factors and evaluate potential solutions, emphasizing the synergistic potential of innovative engineering strategies, combination approaches, and emerging technologies to forge the next generation of cellular immunotherapies for solid tumors.

• Publication year

  2026

• Venue

  Cancer Cell

• Publication date

  2026-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ccell.2026.02.002PMID 41759519PMCID PMC12952687
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Single-cell and spatial transcriptomics reveal mechanisms of radioresistance and immune escape in recurrent nasopharyngeal carcinoma

  2025cited by this paper
• Single-cell spatial transcriptomics unravels cell states and ecosystems associated with clinical response to immunotherapy

  2025cited by this paper
• Emerging insights into lineage plasticity in pancreatic cancer initiation, progression, and therapy resistance.

  2025cited by this paper
• Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial

  2025cited by this paper
• CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells

  2025cited by this paper
• Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency.

  2025cited by this paper
• Tumor cell heterogeneity drives spatial organization of the intratumoral immune response.

  2025cited by this paper
• Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies

  2025cited by this paper
• Engineered natural killer cells for cancer therapy.

  2025cited by this paper
• Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure.

  2025cited by this paper
• In vivo CAR-T cell engineering: concept, research progress, potential challenges and enhancement strategies

  2025cited by this paper
• Single-cell spatial transcriptomics reveals immunotherapy-driven bone marrow niche remodeling in AML

  2025cited by this paper
• Pseudoprogression in CAR-T cell therapy for solid tumor: Case report

  2025cited by this paper
• Cancer immune evasion, immunoediting and intratumour heterogeneity

  2025cited by this paper
• Regional and intratumoral adoptive T-cell therapy

  2024cited by this paper
• Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas

  2024cited by this paper
• Mining nucleic acid “omics” to boost liquid biopsy in cancer

  2024cited by this paper
• Unanswered questions following reports of secondary malignancies after CAR-T cell therapy

  2024cited by this paper
• Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies.

  2024cited by this paper
• Engineered receptors for soluble cellular communication and disease sensing

  2024cited by this paper
• Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial

  2024cited by this paper
• Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial

  2024cited by this paper
• Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies.

  2024cited by this paper
• Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy

  2024cited by this paper
• Cytokines drive the formation of memory-like NK cell subsets via epigenetic rewiring and transcriptional regulation

  2024cited by this paper
• Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma.

  2024cited by this paper
• Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control

  2024cited by this paper
• Empowering pancreatic tumor homing with augmented anti-tumor potency of CXCR2-tethered CAR-NK cells

  2024cited by this paper
• Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD.

  2024cited by this paper
• CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors

  2024cited by this paper
• ATHENA: A phase 1/2 study of AZD5851, a chimeric antigen receptor (CAR) T-cell therapy directed against GPC3 in adult patients with advanced/recurrent hepatocellular carcinoma (HCC).

  2024cited by this paper
• Engineering immune-evasive allogeneic cellular immunotherapies

  2024cited by this paper
• FOXO1 is a master regulator of memory programming in CAR T cells

  2024cited by this paper
• Locoregional delivery of chimeric antigen receptor-T cells: Breaking the spell in glioblastoma?

  2024cited by this paper
• Liquid biopsy in cancer: current status, challenges and future prospects

  2024cited by this paper
• Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management

  2024cited by this paper
• Risk of second malignancies and T-cell lymphoma after chimeric antigen receptor T-cell therapy

  2024cited by this paper
• Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment

  2024cited by this paper
• Cell membrane-anchored and tumor-targeted IL-12 T-cell therapy destroys cancer-associated fibroblasts and disrupts extracellular matrix in heterogenous osteosarcoma xenograft models

  2024cited by this paper
• Direct in vivo CAR T cell engineering.

  2024cited by this paper
• Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers

  2024cited by this paper
• LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation.

  2024cited by this paper
• Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions

  2024cited by this paper
• Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy

  2024cited by this paper
• Fibroblast activation protein constitutes a novel target of chimeric antigen receptor T‐cell therapy in solid tumors

  2024cited by this paper
• Long-term outcomes following CAR T cell therapy: what we know so far

  2023cited by this paper
• Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I study

  2023cited by this paper
• CAR T-cell detection scoping review: an essential biomarker in critical need of standardization

  2023cited by this paper
• Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma

  2023cited by this paper
• Gene-edited and -engineered stem cell platform drives immunotherapy for brain metastatic melanomas

  2023cited by this paper
• Immune Effector Cell associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS).

  2023cited by this paper
• Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer

  2023cited by this paper
• Decoding the tumor microenvironment with spatial technologies

  2023cited by this paper
• CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn

  2023cited by this paper
• Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant

  2023cited by this paper
• Taming CAR T cell therapy toxicity

  2023cited by this paper
• Arming CAR-T Cells with Cytokines and More: Innovations in the Fourth-Generation CAR-T Development.

  2023cited by this paper
• Cancer-associated fibroblasts: from basic science to anticancer therapy

  2023cited by this paper
• Immune Effector Cell-Associated Hematotoxicity (ICAHT): EHA/EBMT Consensus Grading and Best Practice Recommendations.

  2023cited by this paper
• Detection and quantification of unintended large on-target gene modifications due to CRISPR/Cas9 editing

  2023cited by this paper
• Co-opting signalling molecules enables logic-gated control of CAR T cells

  2023cited by this paper
• GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.

  2023cited by this paper
• Bifunctional cancer cell–based vaccine concomitantly drives direct tumor killing and antitumor immunity

  2023cited by this paper
• Allogeneic CAR T Cell Therapy for Cancer

  2023cited by this paper
• Anakinra for refractory CRS or ICANS after CAR T-cell therapy.

  2023cited by this paper
• Therapy with oncolytic viruses: progress and challenges

  2023cited by this paper
• Whole tumour cell-based vaccines: tuning the instruments to orchestrate an optimal antitumour immune response

  2023cited by this paper
• Safety and efficacy of autologous cell vaccines in solid tumors: a systematic review and meta-analysis of randomized control trials

  2023cited by this paper
• Tumor inflammation-associated neurotoxicity

  2023cited by this paper
• Engineering the next generation of cell-based therapeutics

  2022cited by this paper
• Epigenetic regulation of T cell exhaustion

  2022cited by this paper
• To go or not to go? Biological logic gating engineered T cells

  2022cited by this paper
• Ultrasmall iron oxide nanoparticles cause significant toxicity by specifically inducing acute oxidative stress to multiple organs

  2022cited by this paper
• Engineering Next-Generation CAR-T Cells: Overcoming Tumor Hypoxia and Metabolism.

  2022cited by this paper
• OUP accepted manuscript

  2022cited by this paper
• Programmable eukaryotic protein synthesis with RNA sensors by harnessing ADAR

  2022cited by this paper
• Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy.

  2022cited by this paper
• Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma

  2022cited by this paper
• Assessment of Pretreatment and Posttreatment Evolution of Neurofilament Light Chain Levels in Patients Who Develop Immune Effector Cell–Associated Neurotoxicity Syndrome

  2022cited by this paper
• Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling

  2022cited by this paper
• Cancer vaccines: the next immunotherapy frontier

  2022cited by this paper
• RASA2 ablation in T cells boosts antigen sensitivity and long-term function

  2022cited by this paper
• Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours

  2022cited by this paper
• Synthetic cytokine circuits that drive T cell infiltration into immune-excluded tumors

  2022cited by this paper
• Highly Sensitive EGFRvIII Detection in Circulating Extracellular Vesicle RNA of Glioma Patients

  2022cited by this paper
• Natural killer cells in antitumour adoptive cell immunotherapy

  2022cited by this paper
• Monitoring Therapeutic Response to Anti-Fibroblast Activation Protein (FAP) CAR T Cells using [18F]AlF-FAPI-74.

  2022cited by this paper
• KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.

  2021cited by this paper
• Assessing CAR T-cell therapy response using genome-wide sequencing of cell-free DNA in patients with B-cell lymphomas.

  2021cited by this paper
• CRISPR/Cas-Based Epigenome Editing: Advances, Applications, and Clinical Utility.

  2021cited by this paper
• Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy

  2021cited by this paper
• CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial

  2021cited by this paper
• Metabolic Reprogramming of Terminally Exhausted CD8+ T cells by IL-10 Enhances Anti-Tumor Immunity

  2021cited by this paper
• MRI Guided Focused Ultrasound-Mediated Delivery of Therapeutic Cells to the Brain: A Review of the State-of-the-Art Methodology and Future Applications

  2021cited by this paper
• Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

  2021cited by this paper
• In vivo CART cell imaging: Paving the way for success in CART cell therapy

  2021cited by this paper
• Anti-EGFR VHH-armed death receptor ligand–engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers

  2021cited by this paper
• Applications of nuclear-based imaging in gene and cell therapy: probe considerations

  2021cited by this paper
• Cellular networks controlling T cell persistence in adoptive cell therapy

  2021cited by this paper
• Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors

  2021cited by this paper

• No citing papers are available for this paper.